ID

17232

Description

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00379119

Link

https://clinicaltrials.gov/show/NCT00379119

Keywords

Versions (1)
  1. 9/1/16 9/1/16 -
Uploaded on

September 1, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT00379119

English

Eligibility Prostate Cancer NCT00379119

1 forms  
Criteria
Description

Criteria

histologically confirmed adenocarcinoma of the prostate
Description

adenocarcinoma of the prostate

Data type

boolean

Alias
UMLS CUI [1]
C0007112
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
Description

Radical prostatectomy

Data type

boolean

Alias
UMLS CUI [1]
C0194810
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
Description

androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)

Data type

boolean

Alias
UMLS CUI [1]
C1518041
UMLS CUI [2]
C3495882
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
Description

rising prostate-specific antigen; no objective evidence of metastatic disease

Data type

boolean

Alias
UMLS CUI [1]
C0201544
UMLS CUI [2]
C0027627
prior radiotherapy for serologic progression allowed
Description

Radiotherapy

Data type

boolean

Alias
UMLS CUI [1]
C1522449
did not receive any form of androgen blockade therapy within the past 9 months
Description

androgen blockade therapy

Data type

boolean

Alias
UMLS CUI [1]
C0279492
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Description

no metastatic disease by abdominal/pelvic ct scan and whole-body scan

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0203669
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C1641132
Inclusion Criteria: Patient Characteristics
Description

Inclusion Criteria: Patient Characteristics

Alias
UMLS CUI-1
C0815172
able to tolerate ct scanning in the supine position
Description

CT scan

Data type

boolean

Alias
UMLS CUI [1]
C0040405
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Description

medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0040113
UMLS CUI [2]
C0026896
UMLS CUI [3]
C0024299
UMLS CUI [4]
C0020550
UMLS CUI [5]
C0006625
no autoimmune disorders
Description

autoimmune disorders

Data type

boolean

Alias
UMLS CUI [1]
C0004364
no acute illness, including active infection requiring antibiotics
Description

no acute illness, including active infection

Data type

boolean

Alias
UMLS CUI [1]
C0001314
UMLS CUI [2]
C0009450
prior concurrent therapy: see disease characteristics
Description

concurrent therapy

Data type

boolean

Alias
UMLS CUI [1]
C0009429
no prior systemic chemotherapy
Description

systemic chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C1883256
no prior immunological therapy
Description

immunological therapy

Data type

boolean

Alias
UMLS CUI [1]
C0021083
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
Description

antiandrogen

Data type

boolean

Alias
UMLS CUI [1]
C0002842
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
Description

5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals

Data type

boolean

Alias
UMLS CUI [1]
C2936788
UMLS CUI [2]
C0756934
UMLS CUI [3]
C0014939
no concurrent systemic steroid therapy (topical steroids allowed)
Description

systemic steroids

Data type

boolean

Alias
UMLS CUI [1]
C2825233
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT00379119

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
adenocarcinoma of the prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Radical prostatectomy
Item
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
boolean
C0194810 (UMLS CUI [1])
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)
Item
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
boolean
C1518041 (UMLS CUI [1])
C3495882 (UMLS CUI [2])
rising prostate-specific antigen; no objective evidence of metastatic disease
Item
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
boolean
C0201544 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
Radiotherapy
Item
prior radiotherapy for serologic progression allowed
boolean
C1522449 (UMLS CUI [1])
androgen blockade therapy
Item
did not receive any form of androgen blockade therapy within the past 9 months
boolean
C0279492 (UMLS CUI [1])
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Item
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
boolean
C0027627 (UMLS CUI [1,1])
C0203669 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C1641132 (UMLS CUI [2,2])
Item Group
Inclusion Criteria: Patient Characteristics
C0815172 (UMLS CUI-1)
CT scan
Item
able to tolerate ct scanning in the supine position
boolean
C0040405 (UMLS CUI [1])
medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Item
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
boolean
C0012634 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0040113 (UMLS CUI [1,3])
C0026896 (UMLS CUI [2])
C0024299 (UMLS CUI [3])
C0020550 (UMLS CUI [4])
C0006625 (UMLS CUI [5])
autoimmune disorders
Item
no autoimmune disorders
boolean
C0004364 (UMLS CUI [1])
no acute illness, including active infection
Item
no acute illness, including active infection requiring antibiotics
boolean
C0001314 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
concurrent therapy
Item
prior concurrent therapy: see disease characteristics
boolean
C0009429 (UMLS CUI [1])
systemic chemotherapy
Item
no prior systemic chemotherapy
boolean
C1883256 (UMLS CUI [1])
immunological therapy
Item
no prior immunological therapy
boolean
C0021083 (UMLS CUI [1])
antiandrogen
Item
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
boolean
C0002842 (UMLS CUI [1])
5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals
Item
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
boolean
C2936788 (UMLS CUI [1])
C0756934 (UMLS CUI [2])
C0014939 (UMLS CUI [3])
systemic steroids
Item
no concurrent systemic steroid therapy (topical steroids allowed)
boolean
C2825233 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial